Status Epilepticus Market Size to Reach USD 2.1 Billion by 2032 | CAGR: 5.1%| DataHorizzon Research

Fort Collins, Colorado, Sept. 06, 2023 (GLOBE NEWSWIRE) — DataHorizzon Research Published a report titled, “Status Epilepticus Market Size, Share, Growth Statistics Analysis Report By Type (Convulsive Status Epilepticus And Non-Convulsive Status Epilepticus), By Medication, By Distribution Channel, By Region, And Segment Forecasts 2023-2032.”  

According to DataHorizzon Research, the status epilepticus market size was valued at USD 1.3 Billion in 2022 and is expected to reach USD 2.1 Billion by 2032 and exhibit a CAGR of 5.1%.  The growing prevalence of epilepsy is projected towards drug development, which is expected to foster market development. In addition, large players’ research and development initiatives have a robust impact on market growth as pharmaceutical companies focus on developing formulations for new routes of administration. The drug approvals by the official authorities provide opportunities for the R&D of novel drugs.

Request Sample Report: https://datahorizzonresearch.com/request-sample-pdf/status-epilepticus-market-2332

Report Snapshot:

Report Title	Status Epilepticus Market
Market Size in 2022	USD 1.3 Billion
Market Size by 2032	USD 2.1 Billion
CAGR from 2023 to 2032	5.1%
Largest Market	North America
Forecast Period	2023 to 2032
Historic Period	2021
Base Year	2022
Report Scope & Coverage	Market size, estimations, competitor analysis, trends, and growth factors
By Type	Convulsive status epilepticus, non-convulsive status epilepticus
By Medication	First-generation, second-generation, and third-generation neuromodulation devices
By Distribution Channel	Hospital pharmacies, retail pharmacies, and online pharmacies
Region	North America, Europe, Asia-Pacific, Latin America, and Middle-East & Africa
Countries Covered	U.S., Canada, U.K., Germany, France, China, India, Japan, South Korea, Brazil, Mexico, UAE, Saudi Arabia, and South Africa, among others
Major Market Players	SAGE Therapeutics, Marinus Pharmaceuticals, H. Lundbeck, CURx Pharmaceuticals, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., GlaxoSmithKline plc, Johnson & Johnson, LivaNova PLC, Eisai Co., Ltd, Medtronic, UCB S.A., NeuroPace, Inc, Jazz Pharmaceuticals, Inc, Novartis AG, Abbott. .

Segmentation Overview:

The global market has been segmented as type, medication, distribution channel, and region. Convulsive status epilepticus leads the type segment owing to their demand and urgency during treatment procedures. First-generation drugs are leading in the medication segment due to their efficacy and the rollout of novel drugs. Hospital pharmacies accounted for a prominent position in 2022 due to the need for emergency treatment of seizures.

North America is the leading market for status epilepticus with a high share and is projected to remain at a high position throughout the forecast period. Leading companies with significant investments in research and development programs and a high patient pool with epilepsy are anticipated to contribute to the market growth.

Key Developments in the Industry:

• In 2022, the U.S. FDA approved Midazolam autoinjector for treating Status Epilepticus. This offers a broader scope for manufacturing companies to promote innovation in novel drug development. 

• In 2022, Marinus Pharmaceuticals Inc. resumed screening Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE). The trials had been suspended as the data monitoring committee reviewed safety parameters in the clinical data safety to conclude that the patients treated with IV ganaxolone were safe. Later, in 2022, the trials were resumed with a new batch of IV formulations that can be cryopreserved during the trial phases with an extended shelf life of 24 months.

Buy This Research Report: https://datahorizzonresearch.com/checkout-page/status-epilepticus-market-2332

Status Epilepticus Market Report Highlights:

• The status epilepticus market is projected at a CAGR of 5.1% by 2032. The research and development is majorly focused on creating a new route of administration for a particular drug is expected to drive market growth.

• Drug approvals by official authorities offer novel opportunities for the market. Besides, pharmaceutical companies also emphasize formulating new routes of administration.

• The convulsive segment accounted for a significant market share in 2022 based on type. Under convulsive status epilepticus, the patient requires immediate emergency treatment because it can prove fatal for patients.

• First-generation drugs dominated the medication segment in 2022, registering a high market share. These drugs can be administered through multiple routes.

• Hospital pharmacies dominated with a high market share, accounting for a dominant position in the global market.

• North America is projected to account for a prominent position in the global market attributed to the presence of leading pharmaceutical companies in the region and significant investments in research and development by the key players.

• Some of the prominent players in the status epilepticus market report include SAGE Therapeutics, Marinus Pharmaceuticals, H. Lundbeck, CURx Pharmaceuticals, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., GlaxoSmithKline plc, Johnson & Johnson, LivaNova PLC, Eisai Co., Ltd, Medtronic, UCB S.A., NeuroPace, Inc, Jazz Pharmaceuticals, Inc, Novartis AG, and Abbott Laboratories.

Looking Exclusively For Region/Country Specific Report? https://datahorizzonresearch.com/ask-for-customization/status-epilepticus-market-2332

OR

Ask For Discount https://datahorizzonresearch.com/ask-for-discount/status-epilepticus-market-2332

Status Epilepticus Market Segmentation:

Status Epilepticus Market, By Type (2023-2032)

• Convulsive status epilepticus
• Non-convulsive status epilepticus 

Status Epilepticus Market, By Medication (2023-2032)

• First-generation
• Second-generation
• Third-generation
• Neuromodulation devices 

Status Epilepticus Market, By Distribution Channel (2023-2032)

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies 

Status Epilepticus Market, By Region (2023-2032)

• North America

• • U.S.
  • Canada

• Europe

• • U.K.
  • Germany
  • France
  • Rest of Europe

• Asia Pacific

• • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific

• Latin America

• • Brazil
  • Mexico
  • Rest of Latin America

• Middle East & Africa

• • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa

About DataHorizzon Research:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

Contact:

Mail: sales@datahorizzonresearch.com

Ph: +1-970-672-0390

Website: https://datahorizzonresearch.com/

Follow Us:  LinkedIn

Recent Publications:

Genetic Testing Market 2023 to 2032

Companion Diagnostics Market 2023 to 2032

Patient Engagement Market 2023 to 2032

Clear Aligners Market 2023 to 2032

Medical Waste Management Market 2032 to 2032

CONTACT: Mail: sales@datahorizzonresearch.com Ph: +1-970-672-0390 Website: https://www.datahorizzonresearch.com 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.